Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Impact of an Antibiotic (Rifaximin) on Liver Scarring in HIV-Infected Patients With Liver Disease

The recruitment status of this study is unknown because the information has not been verified recently.
Verified October 2012 by Mount Sinai School of Medicine.
Recruitment status was  Recruiting
Sponsor:
Collaborator:
Salix Pharmaceuticals
Information provided by (Responsible Party):
Douglas T. Dieterich, Mount Sinai School of Medicine
ClinicalTrials.gov Identifier:
NCT01654939
First received: July 30, 2012
Last updated: October 24, 2012
Last verified: October 2012
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This study is currently recruiting participants.
  Estimated Study Completion Date: September 2013
  Estimated Primary Completion Date: September 2013 (Final data collection date for primary outcome measure)